

# Oliver Boix

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8954365/publications.pdf>

Version: 2024-02-01

5  
papers

117  
citations

1937685

4  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

139  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pasotuxizumab, a BiTE <sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. <i>Immunotherapy</i> , 2021, 13, 125-141.	2.0	72
2	A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. <i>Clinical Cancer Research</i> , 2021, 27, 6366-6375.	7.0	16
3	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	7.0	16
4	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancers—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. <i>Cancers</i> , 2019, 11, 1987.	3.7	12
5	Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. <i>Clinical Cancer Research</i> , 2022, 28, 2969-2969.	7.0	1